Harari lab

We aim to understand T-cells dynamic and correlates of efficacy in cancer patients treated with experimental immunotherapies and to develop analytical tools and pipelines for applications in immune discovery and in the development of novel strategies of cellular therapies ...


Alexandre Harari

PhD Group leader, Human integrated tumor immunology discovery engine (Hi-TIDe) -T cell discovery, Department of Oncology UNIL & CHUV, Ludwig Institute for Cancer Research Lausanne


Selected Publications

Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.

Racle J, Guillaume P, Schmidt J, (...), Bassani-Sternberg M, Harari A, Gfeller D

Immunity – 2023 Mar 30

Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8(+) T-cell epitopes.

Gfeller D, Schmidt J, Croce G, (...), Cesbron J, Racle J, Harari A

Cell systems – 2023 Jan 4

Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.

Kandalaft LE, Harari A

Cancers – 2021 Nov 19

Sensitive identification of neoantigens and cognate TCRs in human solid tumors.

Arnaud M, Chiffelle J, Genolet R, (...), Bobisse S, Coukos G, Harari A

Nature biotechnology – 2021 Nov 15

The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.

Arnaud M, Bobisse S, Chiffelle J, Harari A

Frontiers in immunology – 2021 Jul 30

Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.

Baumgaertner P, Sankar M, Herrera F, (...), Xenarios I, Guex N, Harari A

Frontiers in immunology – 2021 Apr 30

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.

Tanyi JL, Chiang CL, Chiffelle J, (...), Coukos G, Harari A, Kandalaft LE

NPJ vaccines – 2021 Mar 15

T-cell repertoire analysis and metrics of diversity and clonality.

Chiffelle J, Genolet R, Perez MA, (...), Coukos G, Zoete V, Harari A

Current opinion in biotechnology – 2020 Sep 2

Structural dissimilarity from self drives neoepitope escape from immune tolerance.

Devlin JR, Alonso JA, Ayres CM, (...), Gfeller D, Harari A, Baker BM

Nature chemical biology – 2020 Aug 17

Antitumour dendritic cell vaccination in a priming and boosting approach.

Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE

Nature reviews. Drug discovery – 2020 Aug 6

Biotechnologies to tackle the challenge of neoantigen identification.

Arnaud M, Duchamp M, Bobisse S, (...), Renaud P, Coukos G, Harari A

Current opinion in biotechnology – 2020 Jan 8

Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.

Racle J, Michaux J, Rockinger GA, (...), Jandus C, Bassani-Sternberg M, Gfeller D

Nature biotechnology – 2019 Oct 14

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.

Mastelic-Gavillet B, Navarro Rodrigo B, Décombaz L, (...), Romero P, Harari A, Vigano S

Journal for immunotherapy of cancer – 2019 Oct 10

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, (...), Harari A, Coukos G, Kandalaft LE

Science translational medicine – 2018 Apr 11

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, (...), Kandalaft LE, Coukos G, Harari A

Nature communications – 2018 Mar 15

Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.

Harari A, Rozot V, Bellutti Enders F, (...), Hanekom WA, Bart PA, Pantaleo G

Nature medicine – 2011 Feb 20

Related news


AGORA PRS | June 20th


AGORA PRS | June 6th


PhD Thesis Defense | June 2nd


Ludwig Distinguished Lecture, Prof. Rienk Offringa | May 10th